|
MechanismPAI-1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismPAI-1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.
100 Clinical Results associated with MDI Therapeutics, Inc.
0 Patents (Medical) associated with MDI Therapeutics, Inc.
100 Deals associated with MDI Therapeutics, Inc.
100 Translational Medicine associated with MDI Therapeutics, Inc.